The world’s first HSIL therapy to demonstrate positive results in an international multicenter Phase III clinical trial

The new drug application (NDA) accepted by NMPA in May 2024, expected to fill the gap for non-invasive treatment of precancerous lesions

Reached agreement with the U.S. FDA on Phase III trial design to support U.S. approval. The company is actively seeking global partners to prepare for this U.S. Phase III trial submission